Therefore, in this study, we have presented an innovative strategy for developing multi-epitope peptide-based HER2/neu for breast cancer by incorporating CTL and B-cell peptide epitopes into a single polypeptide that was linked to KLH as a source of Th epitopes and immunostimulant. Here, ERBB2 is linked to breast carcinoma.